VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Full Fiscal Year 2024 Earnings Conference Call and Business Update for Monday, March 31, 2025, at 4:30 p.m. U.S. Eastern Time. The conference call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), Terig Hughes (Group CFO), and Dr. Andrew Retter (Chief Medical Officer).
The call will cover Q4 and full fiscal year 2024 financial results, operating performance, and provide updates on important events from 2024 and upcoming milestones. Investors can access the call through various dial-in numbers: U.S. & Canada (1-877-407-9716, toll-free), U.K. (0 800 756 3429, toll-free), and International (1-201-493-6779). A replay will be available until April 14, 2025.
VolitionRx (NYSE AMERICAN: VNRX) ha programmato la sua Conferenza Stampa sui Risultati Fiscali dell'Anno Completo 2024 e Aggiornamento Aziendale per lunedì 31 marzo 2025, alle 16:30 ora orientale degli Stati Uniti. La conferenza sarà ospitata da importanti dirigenti tra cui Louise Batchelor (Direttore Marketing e Comunicazione del Gruppo), Cameron Reynolds (Presidente e CEO del Gruppo), Terig Hughes (CFO del Gruppo) e il Dr. Andrew Retter (Direttore Medico).
La chiamata tratterà i risultati finanziari del quarto trimestre e dell'intero anno fiscale 2024, le performance operative e fornirà aggiornamenti su eventi significativi del 2024 e traguardi futuri. Gli investitori possono accedere alla chiamata tramite vari numeri di telefono: U.S. & Canada (1-877-407-9716, numero verde), U.K. (0 800 756 3429, numero verde) e Internazionale (1-201-493-6779). Una registrazione sarà disponibile fino al 14 aprile 2025.
VolitionRx (NYSE AMERICAN: VNRX) ha programado su Llamada de Conferencia de Resultados del Año Fiscal Completo 2024 y Actualización Empresarial para el lunes 31 de marzo de 2025, a las 4:30 p.m. hora del Este de EE. UU. La conferencia será dirigida por ejecutivos clave, incluyendo a Louise Batchelor (Directora de Marketing y Comunicaciones del Grupo), Cameron Reynolds (Presidente y CEO del Grupo), Terig Hughes (CFO del Grupo) y el Dr. Andrew Retter (Director Médico).
La llamada cubrirá los resultados financieros del cuarto trimestre y del año fiscal completo 2024, el rendimiento operativo y proporcionará actualizaciones sobre eventos importantes de 2024 y hitos futuros. Los inversores pueden acceder a la llamada a través de varios números de marcado: EE. UU. y Canadá (1-877-407-9716, gratuito), Reino Unido (0 800 756 3429, gratuito) e Internacional (1-201-493-6779). Una repetición estará disponible hasta el 14 de abril de 2025.
VolitionRx (NYSE AMERICAN: VNRX)는 2025년 3월 31일 월요일 오후 4시 30분(미국 동부 시간)에 2024 회계연도 전체 실적 발표 및 비즈니스 업데이트 컨퍼런스 콜을 예정하고 있습니다. 이 컨퍼런스 콜은 루이즈 배처러(그룹 마케팅 및 커뮤니케이션 책임자), 카메론 레이놀즈(회장 겸 그룹 CEO), 테리그 휴즈(그룹 CFO), 앤드류 레터 박사(의료 책임자) 등 주요 경영진이 진행합니다.
이번 콜에서는 2024 회계연도 4분기 및 전체 재무 결과, 운영 성과를 다루고 2024년의 중요한 이벤트와 다가오는 이정표에 대한 업데이트를 제공합니다. 투자자들은 다양한 전화번호를 통해 콜에 접속할 수 있습니다: 미국 및 캐나다 (1-877-407-9716, 무료), 영국 (0 800 756 3429, 무료), 국제 (1-201-493-6779). 재생은 2025년 4월 14일까지 가능합니다.
VolitionRx (NYSE AMERICAN: VNRX) a programmé sa Conférence Téléphonique sur les Résultats de l'Exercice Fiscal Complet 2024 et Mise à Jour de l'Entreprise pour le lundi 31 mars 2025, à 16h30, heure de l'Est des États-Unis. La conférence sera animée par des dirigeants clés, notamment Louise Batchelor (Directrice Marketing et Communication du Groupe), Cameron Reynolds (Président et CEO du Groupe), Terig Hughes (CFO du Groupe) et Dr. Andrew Retter (Médecin en Chef).
La conférence abordera les résultats financiers du quatrième trimestre et de l'exercice fiscal complet 2024, la performance opérationnelle et fournira des mises à jour sur des événements importants de 2024 et des jalons à venir. Les investisseurs peuvent accéder à la conférence via divers numéros de téléphone : États-Unis et Canada (1-877-407-9716, numéro gratuit), Royaume-Uni (0 800 756 3429, numéro gratuit) et International (1-201-493-6779). Un enregistrement sera disponible jusqu'au 14 avril 2025.
VolitionRx (NYSE AMERICAN: VNRX) hat seine Telefonkonferenz zur Bekanntgabe der Ergebnisse des Gesamtjahres 2024 und zur Unternehmensaktualisierung für Montag, den 31. März 2025, um 16:30 Uhr Eastern Time (USA) angesetzt. Die Konferenz wird von wichtigen Führungskräften geleitet, darunter Louise Batchelor (Gruppenleiterin für Marketing und Kommunikation), Cameron Reynolds (Präsident und CEO der Gruppe), Terig Hughes (CFO der Gruppe) und Dr. Andrew Retter (Leitender Arzt).
In der Konferenz werden die finanziellen Ergebnisse des vierten Quartals und des gesamten Geschäftsjahres 2024 sowie die operative Leistung behandelt und es werden Updates zu wichtigen Ereignissen aus 2024 und bevorstehenden Meilensteinen gegeben. Investoren können über verschiedene Einwahlnummern auf die Konferenz zugreifen: USA & Kanada (1-877-407-9716, gebührenfrei), Großbritannien (0 800 756 3429, gebührenfrei) und International (1-201-493-6779). Eine Wiederholung wird bis zum 14. April 2025 verfügbar sein.
- None.
- None.
Conference call to take place on Monday, March 31 at 4:30 p.m.
Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference Call
Date: Monday, March 31, 2025
Time: 4:30 p.m.
Toll/International: 1-201-493-6779
Conference ID: 13752134
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in 2024 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 14, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-fiscal-year-2024-earnings-conference-call-and-business-update-302410637.html
SOURCE VolitionRx Limited
FAQ
When is VolitionRx (VNRX) reporting its full year 2024 earnings?
How can investors access VNRX's Q4 2024 earnings call?
Who will be presenting at VolitionRx's 2024 earnings call?
How long will VNRX's Q4 2024 earnings call replay be available?
